It is a privilege to be associated with the Vet-Stem management team and their exciting and proprietary stem cell technology.
Poway, California (PRWEB) July 11, 2013
Vet-Stem, Inc. is proud to announce the addition of Erwin F. Workman, Jr., PhD, to their Board of Directors. Dr. Workman has over 35 years of successful diagnostic and scientific development experience with IDEXX Laboratories, Inc. (IDXX) and Abbott Laboratories, Inc. (ABT). Dr. Workman’s successes in Research and Development, Business Operations, Manufacturing and Distribution while at IDEXX Laboratories, Inc. are a good marriage with Vet-Stem, Inc.’s decade of development in the field of Regenerative Veterinary Medicine.
Dr. Workman was a key participant in the creation of the world’s largest veterinary diagnostic company, IDEXX Laboratories, Inc. Dr. Workman helped lead IDEXX Laboratories, Inc. through startup, new product development, initial profitability, global expansion and a successful IPO.
Prior to joining IDEXX Laboratories, Inc. Dr. Workman oversaw and directed the Research and Development of the Hepatitis and AIDS business unit of Abbott Laboratories, Inc.
“Dr. Workman will bring many years of proven experience to the Board of Directors, while helping guide Vet-Stem to become a global leader in Regenerative Veterinary Medicine. IDEXX Laboratories, Inc. encountered many of the same growth and new product development challenges facing Vet-Stem, Inc. today. I am proud to have Dr. Workman as a trusted advisor during this phase of rapid expansion and new product development,” states Robert Harman, DVM, CEO and Founder of Vet-Stem, Inc.
“It is a privilege to be associated with the Vet-Stem management team and their exciting and proprietary stem cell technology,” says Dr. Workman. “Vet-Stem has been a pioneer in the field of regenerative medicine for animals and has extensive laboratory and clinical experience with adipose tissue-derived stem cells. The use of these cells offers tremendous therapeutic potential and could revolutionize the way veterinarians treat injuries or disease states where control of pain and regeneration of healthy tissue is crucial.”
Dr. Workman’s position on the Board of Directors for Vet-Stem will serve the purpose of leading strategic planning and execution for current and future services and products. He will compliment the other board members that represent the venture capital perspective (Linda Powers), multi-national agribusiness (Dr. Mike McCloskey), and biotechnology operations and distribution (Mike Dale).
Vet-Stem, Inc. developed and owns patents for fat-derived stem cell veterinary technology to isolate stem and regenerative cells from the animal’s own fat for therapeutic injection into injured areas. Over the last ten years Vet-Stem, Inc.’s lab has provided stem cell services for treatment of more than 10,000 dogs, cats, and horses in the US and Canada.
About Vet-Stem, Inc.
Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.’s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.